Should I buy or sell Mirum Pharmaceuticals stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirum Pharmaceuticals in the last twelve months. There are currently 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MIRM shares. View MIRM analyst ratings or view top-rated stocks .

What is Mirum Pharmaceuticals' stock price target for 2024?

9 Wall Street research analysts have issued twelve-month price targets for Mirum Pharmaceuticals' stock. Their MIRM share price targets range from $35.00 to $72.00. On average, they predict the company's share price to reach $51.70 in the next year. This suggests a possible upside of 118.3% from the stock's current price. View analysts price targets for MIRM or view top-rated stocks among Wall Street analysts .

How have MIRM shares performed in 2024?

Mirum Pharmaceuticals' stock was trading at $29.52 at the beginning of 2024. Since then, MIRM shares have decreased by 19.8% and is now trading at $23.68. View the best growth stocks for 2024 here .

When is Mirum Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our MIRM earnings forecast .

How were Mirum Pharmaceuticals' earnings last quarter?

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) released its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by $0.32. The business earned $69.55 million during the quarter, compared to the consensus estimate of $66.73 million. Mirum Pharmaceuticals had a negative net margin of 86.33% and a negative trailing twelve-month return on equity of 66.24%.

What ETFs hold Mirum Pharmaceuticals' stock?

ETFs with the largest weight of Mirum Pharmaceuticals (NASDAQ:MIRM) stock in their portfolio include Simplify Propel Opportunities ETF (SURI) . Virtus LifeSci Biotech Products ETF (BBP) .

What other stocks do shareholders of Mirum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirum Pharmaceuticals investors own include Pfizer (PFE) , Fulcrum Therapeutics (FULC) , OPKO Health (OPK) , Vaxart (VXRT) , Advanced Micro Devices (AMD) , Matinas BioPharma (MTNB) , Sorrento Therapeutics (SRNE) , Trevena (TRVN) , VBI Vaccines (VBIV) and Dynavax Technologies (DVAX) .

When did Mirum Pharmaceuticals IPO?

Mirum Pharmaceuticals (MIRM) raised $75 million in an initial public offering on Thursday, July 18th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities served as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers.

Who are Mirum Pharmaceuticals' major shareholders?

Mirum Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.14%), Los Angeles Capital Management LLC (0.09%), Wealth Enhancement Advisory Services LLC (0.07%) and Allspring Global Investments Holdings LLC (0.04%). Insiders that own company stock include Christopher Peetz , Eric Bjerkholt, Ian Clements , James E Flynn , John A Maurer, Jolanda Howe, Lara Longpre, Michael G Grey, Niall O'donnell, Pamela Vig , Patrick J Heron and Peter Radovich. View institutional ownership trends .

How do I buy shares of Mirum Pharmaceuticals?

Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:MIRM

Mirum Pharmaceuticals (MIRM) Stock Price, News & Analysis

→ Forget NVIDIA, buy this $2 AI stock now… (From Behind the Markets) (Ad)

Free MIRM Stock Alerts

$23.81

+0.24 (+1.02%)

(As of 04:37 PM ET)

Compare

Today's Range: $23.40
▼
$24.00
50-Day Range: $23.57
▼
$29.93
52-Week Range: $23.29
▼
$35.56

Volume: 336,912 shs
Average Volume: 567,090 shs
Market Capitalization: $1.12 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $51.70

Get Mirum Pharmaceuticals alerts:

Mirum Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.11 Rating Score
Upside/Downside: 118.3% Upside
$51.70 Price Target
Short Interest: Bearish
17.36% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.69
Upright™ Environmental Score
News Sentiment: 0.16
Based on 10 Articles This Week
Insider Trading: Selling Shares
$130,267 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.12) to $1.08 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.23 out of 5 stars

Medical Sector

119th out of 918 stocks

Pharmaceutical Preparations Industry

38th out of 419 stocks

4.6

Analyst's Opinion

Consensus Rating
Mirum Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Mirum Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
17.36% of the outstanding shares of Mirum Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Mirum Pharmaceuticals has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.
Change versus previous month
Short interest in Mirum Pharmaceuticals has recently increased by 0.25%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Mirum Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Mirum Pharmaceuticals does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Mirum Pharmaceuticals has received a 61.01% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Liver-disease medication (A05)", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Mirum Pharmaceuticals is -1.69.

1.8

News and Social Media Coverage

News Sentiment
Mirum Pharmaceuticals has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Mirum Pharmaceuticals this week, compared to 4 articles on an average week.
Search Interest
Only 3 people have searched for MIRM on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Mirum Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Mirum Pharmaceuticals insiders have sold 28.72% more of their company's stock than they have bought. Specifically, they have bought $101,200.00 in company stock and sold $130,267.00 in company stock.
Percentage Held by Insiders
24.06% of the stock of Mirum Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Mirum Pharmaceuticals are expected to grow in the coming year, from ($1.12) to $1.08 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Mirum Pharmaceuticals is -5.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Mirum Pharmaceuticals is -5.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Mirum Pharmaceuticals has a P/B Ratio of 4.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

The #1 Opportunity of the decade?

It's no wonder the Department of Defense is heavily invested in this technology. And why The Pentagon is pouring $20 billion into it.

Click here to learn more >>>

About Mirum Pharmaceuticals Stock (NASDAQ:MIRM)

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

MIRM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MIRM Stock News Headlines

March 28, 2024 | insidertrades.com

Eric Bjerkholt Purchases 2,000 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

March 26, 2024 | insidertrades.com

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells $111,017.40 in Stock

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

March 19, 2024 | insidertrades.com

Eric Bjerkholt Buys 2,000 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

April 19, 2024 | americanbankingnews.com

Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Up to $24.01

April 19, 2024 | americanbankingnews.com

Mirum Pharmaceuticals (NASDAQ:MIRM) Now Covered by Stifel Nicolaus

April 18, 2024 | msn.com

Stifel starts Mirum at buy, cites IBATi drug potential

April 17, 2024 | msn.com

Stifel Initiates Coverage of Mirum Pharmaceuticals (MIRM) with Buy Recommendation

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 17, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Mirum Pharmaceuticals Amidst Strategic Positioning and Treatment Breakthroughs

April 17, 2024 | americanbankingnews.com

Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 1-Year Low at $24.17

April 16, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Mirum Pharmaceuticals Amid Positive Clinical Trial Outlook

April 10, 2024 | businesswire.com

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 9, 2024 | americanbankingnews.com

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Rating of "Buy" from Analysts

April 2, 2024 | finance.yahoo.com

Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome

April 2, 2024 | businesswire.com

Mirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome

March 26, 2024 | finance.yahoo.com

Mirum Pharmaceuticals Inc (MIRM) Insider Sells Shares

March 20, 2024 | investing.com

Mirum Pharmaceuticals COO sells over $28k in company stock

March 18, 2024 | markets.businessinsider.com

Cracking The Code: Understanding Analyst Reviews For Mirum Pharmaceuticals

March 15, 2024 | ca.finance.yahoo.com

MIRM Mar 2024 40.000 call

March 15, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Mirum Pharmaceuticals Following FDA Approval and Promising Pipeline Developments

March 14, 2024 | msn.com

FDA Approves Mirum's Livmarli For Liver Disease In Kids As Young As 5 Years: Analyst Bullish On Label Expansion Strategy

March 14, 2024 | marketwatch.com

Mirum Pharmaceuticals Gets Additional FDA Approval for Livmarli

March 14, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Mirum Pharmaceuticals Following FDA Approval and Positive Revenue Outlook

March 14, 2024 | msn.com

3 Best Stocks to Buy Now, 3/14/2024, According to Top Analysts

March 14, 2024 | msn.com

Mirum gains as FDA accepts label expansion of liver disease drug

March 13, 2024 | reuters.com

US FDA approves expanded use of Mirum's liver disease drug

See More Headlines

Receive MIRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:MIRM
CUSIP: N/A
CIK: 1759425
Web: mirumpharma.com
Phone: (650) 667-4085
Fax: N/A
Employees: 264
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $51.70
High Stock Price Target: $72.00
Low Stock Price Target: $35.00
Potential Upside/Downside: +119.2%
Consensus Rating: Buy
Rating Score (0-4): 3.11
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.97)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-163,410,000.00
Net Margins: -86.33%
Pretax Margin: -87.15%
Return on Equity: -66.24%
Return on Assets: -23.55%

Debt

Debt-to-Equity Ratio: 1.23
Current Ratio: 4.45
Quick Ratio: 4.19

Sales & Book Value

Annual Sales: $186.37 million
Price / Sales: 5.95
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.33 per share
Price / Book: 4.43

Miscellaneous

Outstanding Shares: 47,000,000
Free Float: 35,694,000
Market Cap: $1.11 billion
Optionable: Optionable
Beta: 1.14

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Mr. Christopher Peetz (Age 45)
CEO & Director
Comp: $1.09M
Mr. Peter Radovich M.B.A. (Age 46)
Ph.D., COO & President
Comp: $732.15k
Dr. Pamela Vig Ph.D. (Age 53)
Chief Scientific Officer & Head of Research
Comp: $678.2k
Ms. Lara Longpre MBA (Age 54)
MSC, Chief Development Officer
Comp: $678.2k
Mr. Eric H. Bjerkholt M.B.A. (Age 64)
Chief Financial Officer
Andrew McKibben
Vice President of Investor Relations and Finance
Mr. Paul K. Ross
Chief Compliance Officer
Ms. Erin Campany (Age 56)
Senior Vice President of Human Resources
Dr. Ian Clements Ph.D. (Age 55)
Consultant
Comp: $649.1k
Ms. Vinita P. Kumar
Senior vice President of Quality

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MIRM Stock Analysis - Frequently Asked Questions

Should I buy or sell Mirum Pharmaceuticals stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirum Pharmaceuticals in the last twelve months. There are currently 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MIRM shares.
View MIRM analyst ratings or view top-rated stocks.
What is Mirum Pharmaceuticals' stock price target for 2024?: 9 Wall Street research analysts have issued twelve-month price targets for Mirum Pharmaceuticals' stock. Their MIRM share price targets range from $35.00 to $72.00. On average, they predict the company's share price to reach $51.70 in the next year. This suggests a possible upside of 118.3% from the stock's current price.
View analysts price targets for MIRM or view top-rated stocks among Wall Street analysts.
How have MIRM shares performed in 2024?: Mirum Pharmaceuticals' stock was trading at $29.52 at the beginning of 2024. Since then, MIRM shares have decreased by 19.8% and is now trading at $23.68.
View the best growth stocks for 2024 here.
When is Mirum Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our MIRM earnings forecast.
How were Mirum Pharmaceuticals' earnings last quarter?: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) released its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by $0.32. The business earned $69.55 million during the quarter, compared to the consensus estimate of $66.73 million. Mirum Pharmaceuticals had a negative net margin of 86.33% and a negative trailing twelve-month return on equity of 66.24%.
What ETFs hold Mirum Pharmaceuticals' stock?: ETFs with the largest weight of Mirum Pharmaceuticals (NASDAQ:MIRM) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).Virtus LifeSci Biotech Products ETF (BBP).

What other stocks do shareholders of Mirum Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Mirum Pharmaceuticals investors own include Pfizer (PFE), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Vaxart (VXRT), Advanced Micro Devices (AMD), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV) and Dynavax Technologies (DVAX).
When did Mirum Pharmaceuticals IPO?: Mirum Pharmaceuticals (MIRM) raised $75 million in an initial public offering on Thursday, July 18th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Citigroup, Evercore ISI and Guggenheim Securities served as the underwriters for the IPO and Raymond James and Roth Capital Partners were co-managers.
Who are Mirum Pharmaceuticals' major shareholders?: Mirum Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.14%), Los Angeles Capital Management LLC (0.09%), Wealth Enhancement Advisory Services LLC (0.07%) and Allspring Global Investments Holdings LLC (0.04%). Insiders that own company stock include Christopher Peetz, Eric Bjerkholt, Ian Clements, James E Flynn, John A Maurer, Jolanda Howe, Lara Longpre, Michael G Grey, Niall O'donnell, Pamela Vig, Patrick J Heron and Peter Radovich.
View institutional ownership trends.
How do I buy shares of Mirum Pharmaceuticals?: Shares of MIRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MIRM) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Mirum Pharmaceuticals (MIRM) Stock Price, News & Analysis

Mirum Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Mirum Pharmaceuticals Stock (NASDAQ:MIRM)

MIRM Stock Price History

MIRM Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

MIRM Stock Analysis - Frequently Asked Questions

Overall MarketRank^™